Many issues in store for new FDA commissioner

Abstract

What should be at the top of the agenda for Andrew von Eschenbach, the new interim commissioner of the US Food and Drug Administration? Opinions among agency-watchers vary, from dramatically cutting back direct-to-consumer advertising to ditching placebo arms in late-stage cancer clinical trials. But most observers agree on one thing: the under-fire agency… (More)
DOI: 10.1038/nrd1894

Topics

  • Presentations referencing similar topics